Fresh Equities
BOTANIX PHARMACEUTICALS LTD

BOTANIX PHARMACEUTICALS LTD

ASX:BOT

Company Information

At Botanix Pharma, we are dedicated to developing next generation therapeutics for the treatment of serious skin diseases. Our mission is to improve the lives of patients battling acne, psoriasis and atopic dermatitis, by providing new treatment options for conditions that currently are inadequately addressed or are treated with therapeutics that are burdened with side effects profiles. We are harnessing the untapped potential of a synthetic active pharmaceutical ingredient known as cannabidiol which is currently being studied for the treatment of epilepsy, pain, arthritis and schizophrenia amongst other indications. Botanix is preparing for the first human trials utilizing synthetic cannabidiol in a proprietary drug delivery system (Permetrex™) for direct skin delivery of the therapy.

Type

Listed Company

GICS Sub-Industry

Biotechnology

Head Office

68 Aberdeen St, Northbridge WA 6003, Australia

Biotechnology
Health Care

Quarterly Cash Flows

The numbers below are derived from quarterly cash flow reports provided by the company. Fresh Equities does not guarantee that the information provided is accurate, you can read the associated report by clicking read more for the quarter. Always do your own research and do not rely on the information provided here as your only source of research.



Fresh Equities

Copyright © 2018 Fresh Equities. All rights reserved.

ACN 619 657 028. CAR: 001267539 of AFSL: 471379.
Archive
Support
This website does not constitute an offer to sell, a solicitation of an offer to buy, or a recommendation of any security or any other product or service by Fresh Equities Pty Ltd, its representatives or any other third party regardless of whether such security, product or service is referenced on this website.